The Antibiotic Era is ending
MatriSys Bio is a clinical stage Specialty Biopharmaceutical Company focused on developing and commercializing rational microbiome therapies for the top five dermatology and skin care conditions.
Recent scientific advances have demonstrated that some commensal bacteria, “Good Bugs” residing on human skin are beneficial to our immune defense. In contrast, colonization by “Bad Bugs”, for example Staph. aureus on the skin of patients with atopic dermatitis, is detrimental.
Re-Balancing the Skin Microbiome & Innate Immune System
MatriSys Bioscience is a Clinical Stage Specialty Biopharmaceutical Company for the post antibiotic era. Our company focuses on dermatology and skin care and develops therapeutics at the interface of the microbiome revolution and the innate immune system. Historically bacteria have been considered as natural enemies that must be fought. However, recent advances in skin microbiome research have led to a better understanding of the mutualistic beneficial relationships that exist between the highly diverse skin microbial community and skin health.
Commercialization
Our Intellectual Property offers multiple routes for commercialization: Rx Dermatology, Skin Care, and Cosmetic. Licensing discussions are currently underway for our first asset, S. hominis.
Publications & News
-
S. epidermidis Influence on Host Immunity: More Than Skin Deep – Richard L. Gallo
Mammalian skin is a highly complex semipermeable filtration system that we now know to have many...
-
Dermal adipocytes protect against invasive Staphylococcus aureus skin infection - Ling-juan Zhang, Christian F. Guerrero-Juarez, Tissa Hata, Sagar P. Bapat, Raul Ramos, Maksim V. Plikus and Richard L. Gallo
Adipocytes have been suggested to be immunologically active, but their role in host defense is...
-
Structure and function of the human skin microbiome - Nina N. Schommer and Richard L. Gallo
An abundant and diverse collection of bacteria, fungi, and viruses inhabits the human skin. These...